Related Experiment Video
Updated: Jul 1, 2026
A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function
Namita Kundu1, Xinrong Ma, Dawn Holt
1Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Abstract:
Cyclooxygenase-2 (COX-2) is associated with aggressive breast cancers. The COX-2 product prostaglandin E(2) (PGE(2)) acts through four G-protein-coupled receptors designated EP1-4. Malignant and immortalized normal mammary epithelial cell lines express all four EP. The EP4 antagonist AH23848 reduced the ability of tumor cells to colonize the lungs or to spontaneously metastasize from the mammary gland. EP4 gene silencing by shRNA also reduced the ability of mammary tumor cells to metastasize. Metastasis inhibition was lost in mice lacking either functional Natural Killer (NK) cells or interferon-gamma. EP4 antagonism inhibited MHC class I expression resulting in enhanced ability of NK cells to lyse mammary tumor target cells. These studies support the hypothesis that EP4 receptor antagonists reduce metastatic potential by facilitating NK-mediated tumor cell killing and that therapeutic targeting of EP4 may be an alternative approach to the use of COX inhibitors to limit metastatic disease.
Insights
Targeting the EP4 receptor, a product of cyclooxygenase-2 (COX-2), can inhibit breast cancer metastasis. This approach enhances natural killer (NK) cell activity against tumor cells, offering a potential alternative to COX inhibitors.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in aggressive breast cancers.
- Prostaglandin E(2) (PGE(2)), a COX-2 product, signals through EP1-4 receptors.
- Mammary epithelial cells express all four EP receptors.
Purpose of the Study:
- To investigate the role of EP4 receptor signaling in breast cancer metastasis.
- To evaluate the therapeutic potential of EP4 antagonists in reducing metastasis.
Main Methods:
- Treatment with EP4 antagonist AH23848.
- Gene silencing of EP4 using shRNA.
- Assessment of metastasis in immunocompetent and immunodeficient mouse models.
- Evaluation of Natural Killer (NK) cell activity and MHC class I expression.
Main Results:
- EP4 antagonism significantly reduced tumor cell colonization and spontaneous metastasis.
- EP4 gene silencing also inhibited mammary tumor cell metastasis.
- Metastasis inhibition was dependent on functional Natural Killer (NK) cells and interferon-gamma.
- EP4 antagonism decreased MHC class I expression, enhancing NK cell-mediated tumor cell lysis.
Conclusions:
- EP4 receptor antagonists reduce breast cancer metastatic potential by enhancing NK cell-mediated tumor cell killing.
- Targeting EP4 offers a potential therapeutic strategy for metastatic breast cancer, independent of traditional COX inhibitors.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:38Mitogens and the Cell Cycle
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...